

Table 4.27

## Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2003-2007  
Females by Race

Histology <sup>a</sup>	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native <sup>b</sup>		Hispanic <sup>c</sup>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma <sup>d</sup>	60,394	99.7%	49,063	99.7%	5,355	99.4%	5,028	99.8%	164	100.0%	4,920	99.7%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	18	0.0%	17	0.0%	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> <sup>f</sup>	50,554	83.4%	40,642	82.6%	4,644	86.2%	4,574	90.8%	127	77.4%	4,198	85.0%
Cribriform carcinoma <i>in situ</i> (8201/2)	4,844	8.0%	3,863	7.8%	403	7.5%	484	9.6%	17	10.4%	413	8.4%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	3,092	5.1%	2,584	5.3%	211	3.9%	269	5.3%	-	-	224	4.5%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	20,986	34.6%	17,054	34.7%	1,942	36.1%	1,687	33.5%	63	38.4%	1,675	33.9%
Comedocarcinoma <i>in situ</i> (8501/2)	4,568	7.5%	3,762	7.6%	396	7.4%	364	7.2%	-	-	386	7.8%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,144	1.9%	841	1.7%	156	2.9%	113	2.2%	-	-	97	2.0%
Noninfiltrating intracystic carcinoma(8504/2)	300	0.5%	211	0.4%	38	0.7%	47	0.9%	-	-	28	0.6%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,656	2.7%	1,335	2.7%	182	3.4%	113	2.2%	-	-	150	3.0%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	13,758	22.7%	10,820	22.0%	1,308	24.3%	1,473	29.2%	19	11.6%	1,205	24.4%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	6,974	11.5%	6,031	12.3%	466	8.7%	264	5.2%	21	12.8%	506	10.3%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	6,948	11.5%	6,009	12.2%	463	8.6%	263	5.2%	21	12.8%	506	10.3%
Lobular CIS <sup>f</sup> with other CIS <sup>f</sup> (8524/2)	24	0.0%	20	0.0%	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,405	4.0%	2,025	4.1%	196	3.6%	152	3.0%	-	-	188	3.8%
Other adenocarcinomas <sup>g</sup>	443	0.7%	348	0.7%	49	0.9%	37	0.7%	-	-	28	0.6%
Other <i>in situ</i> histologies <sup>h</sup>	192	0.3%	148	0.3%	31	0.6%	-	-	-	-	16	0.3%
Total	60,586	100.0%	49,211	100.0%	5,386	100.0%	5,037	100.0%	164	100.0%	4,936	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Percents may not sum to 100 due to rounding.

<sup>a</sup> Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

<sup>b</sup> Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

<sup>d</sup> Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>e</sup> Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

<sup>f</sup> Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

<sup>f</sup> CIS = Carcinoma *in situ*.

<sup>g</sup> Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

<sup>h</sup> Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.